Harmony Biosciences (HRMY) CFO Kapadia sells 20,961 shares under 10b5-1 plan

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. reported an insider sale by its chief financial officer, Sandip Kapadia. On January 15, 2026, Kapadia sold 20,961 shares of Harmony Biosciences common stock in an open-market transaction coded as a sale. The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to trade according to a preset schedule. The weighted average sale price was $35.9159 per share, with individual trades executed between $35.68 and $36.10. After this transaction, the Form 4 reports that Kapadia directly beneficially owned 0 shares of the company’s common stock.

Insider Trade Summary

Net Seller: 20,961 shares ($752,833)

Net Sell 1 txn

Insider Kapadia Sandip

Role CHIEF FINANCIAL OFFICER

Sold 20,961 shs ($753K)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,961	$35.9159	$753K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kapadia Sandip

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

630 W GERMANTOWN PIKE, SUITE 215

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		S(1)		20,961	D	$35.9159(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Christian Ulrich, Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Harmony Biosciences (HRMY) report in this Form 4?

The Form 4 reports that chief financial officer Sandip Kapadia sold 20,961 shares of Harmony Biosciences common stock on January 15, 2026 in an open-market sale.

At what price did the HRMY CFO sell shares in this Form 4 filing?

The reported weighted average sale price was $35.9159 per share, with individual transactions executed between $35.68 and $36.10 per share.

Was the Harmony Biosciences (HRMY) insider sale made under a Rule 10b5-1 plan?

Yes. The filing notes that the sales were effected pursuant to a Rule 10b5-1 trading plan, which pre-schedules trades for insiders.

How many Harmony Biosciences (HRMY) shares does the CFO hold after this reported sale?

Following the reported transaction, the Form 4 shows that Sandip Kapadia directly beneficially owned 0 shares of Harmony Biosciences common stock.

What type of ownership is reported for the HRMY CFO’s transaction?

The transaction is reported as involving Common Stock held with direct (D) ownership, and the sale reduced the directly owned balance to zero shares.

Does the Form 4 for Harmony Biosciences (HRMY) provide details on the trade price range?

Yes. The filing states the shares were sold in multiple transactions at prices ranging from $35.68 to $36.10, with a weighted average price of $35.9159 per share.